![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H23N3O2 |
Molar mass | 325.412 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
ABT-670 is a drug which acts as a potent, orally bioavailable dopamine agonist selective for the D4 subtype, which was developed as a possible treatment for erectile dysfunction,[1] although its current uses are limited to scientific research.[2]
See also
[edit]- ABT-724
- Bremelanotide
- Cabergoline
- Flibanserin
- Intrinsa
- Melanotan II
- Pramipexole
- PF-219,061
- Tibolone
- UK-414,495
References
[edit]- ^ Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, et al. (December 2006). "Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction". Journal of Medicinal Chemistry. 49 (25): 7450–65. doi:10.1021/jm060662k. PMID 17149874.
- ^ Richards N, Wayman C, Allers KA (November 2009). "Electrophysiological actions of the dopamine agonist apomorphine in the paraventricular nucleus during penile erection". Neuroscience Letters. 465 (3): 242–7. doi:10.1016/j.neulet.2009.08.078. PMID 19733217. S2CID 27767274.